
India's GLP-1 Opportunity: Startups Betting Big on Weight Loss
With semaglutide's patent expired in India, over 50 generic brands are flooding the market at competitive prices, fueling a five-fold GLP-1 expansion to ₹5,000 crore by 2030. Startups like HealthifyRx, VLCC, Sugarfit, and FITPASS are redefining weight loss with holistic programs combining drugs, coaching, and muscle preservation. Investors warn that only comprehensive care models will thrive amid rising competition.







